...
首页> 外文期刊>Cancer Cell >Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy.
【24h】

Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy.

机译:BIM驱动的凋亡在上皮肿瘤和合理化疗中的关键作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Defective apoptosis not only promotes tumorigenesis, but also can confound chemotherapeutic response. Here we demonstrate that the proapoptotic BH3-only protein BIM is a tumor suppressor in epithelial solid tumors and also is a determinant in paclitaxel sensitivity in vivo. Furthermore, the H-ras/mitogen-activated protein kinase (MAPK) pathway conferred resistance to paclitaxel that was dependent on functional inactivation of BIM. Whereas paclitaxel induced BIM accumulation and BIM-dependent apoptosis in vitro and in tumors in vivo, the H-ras/MAPK pathway suppressed this BIM induction by phosphorylating BIM and targeting BIM for degradation in proteasomes. The proteasome inhibitor Velcade (P-341, Bortezomib) restored BIM induction, abrogated H-ras-dependent paclitaxel resistance, and promoted BIM-dependent tumor regression, suggesting the potential benefits of combinatorial chemotherapy of Velcade and paclitaxel.
机译:有缺陷的凋亡不仅促进肿瘤发生,而且还会混淆化学疗法的反应。在这里,我们证明了仅凋亡的BH3蛋白BIM是上皮实体瘤中的肿瘤抑制因子,也是体内紫杉醇敏感性的决定因素。此外,H-ras /丝裂原激活的蛋白激酶(MAPK)通路赋予了对紫杉醇的抗药性,这取决于BIM的功能失活。紫杉醇在体外和体内肿瘤诱导BIM积累和BIM依赖性细胞凋亡,而H-ras / MAPK途径通过磷酸化BIM并靶向BIM降解蛋白酶体来抑制BIM诱导。蛋白酶体抑制剂Velcade(P-341,Bortezomib)恢复了BIM诱导,废除了H-ras依赖性紫杉醇耐药性,并促进了BIM依赖性肿瘤消退,表明Velcade和紫杉醇联合化疗的潜在益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号